Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

Lancet
Eitan KeremMichael Wilschanski

Abstract

In about 10% of patients worldwide and more than 50% of patients in Israel, cystic fibrosis results from nonsense mutations (premature stop codons) in the messenger RNA (mRNA) for the cystic fibrosis transmembrane conductance regulator (CFTR). PTC124 is an orally bioavailable small molecule that is designed to induce ribosomes to selectively read through premature stop codons during mRNA translation, to produce functional CFTR. This phase II prospective trial recruited adults with cystic fibrosis who had at least one nonsense mutation in the CFTR gene. Patients were assessed in two 28-day cycles. During the first cycle, patients received PTC124 at 16 mg/kg per day in three doses every day for 14 days, followed by 14 days without treatment; in the second cycle, patients received 40 mg/kg of PTC124 in three doses every day for 14 days, followed by 14 days without treatment. The primary outcome had three components: change in CFTR-mediated total chloride transport; proportion of patients who responded to treatment; and normalisation of chloride transport, as assessed by transepithelial nasal potential difference (PD) at baseline, at the end of each 14-day treatment course, and after 14 days without treatment. The trial was registe...Continue Reading

References

Dec 17, 1981·The New England Journal of Medicine·M KnowlesR Boucher
Mar 1, 1995·American Journal of Respiratory and Critical Care Medicine·M R KnowlesR C Boucher
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·J P ClancyD M Bedwell
Aug 9, 2001·The European Respiratory Journal·M WilschanskiE Kerem
Jul 4, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Pamela L ZeitlinLois Brass-Ernst
Sep 13, 2002·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ming DuDavid M Bedwell
Aug 9, 2003·Chest·Michael P BoyleUNKNOWN Cystic Fibrosis Therapeutics Development Network Nasal PD Study Group
Oct 10, 2003·The New England Journal of Medicine·Michael WilschanskiEitan Kerem
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Daniel SchülerMichael R Knowles
Feb 15, 2005·American Journal of Respiratory and Critical Care Medicine·Isabelle Sermet-GaudelusAleksander Edelman
Dec 22, 2005·Pediatric Pulmonology·Omotola UwaifoCarol J Blaisdell
Jul 15, 2006·American Journal of Respiratory and Critical Care Medicine·Michael WilschanskiPeter Durie
Nov 14, 2006·Chest·Edward F McKoneMoira L Aitken
Jul 13, 2007·European Journal of Human Genetics : EJHG·Liat LindeBatsheva Kerem
Aug 3, 2007·Genes & Development·Olaf Isken, Lynne E Maquat
Sep 25, 2007·Chest·Yasmin YaakovMichael Wilschanski
Feb 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ming DuDavid M Bedwell

❮ Previous
Next ❯

Citations

Jul 23, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Steven M RoweDavid M Bedwell
Jan 22, 2011·Journal of Inherited Metabolic Disease·Lu TanMichael J Bennett
Jun 23, 2009·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·I Sermet-GaudelusG Lenoir
Jun 18, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·K De BoeckUNKNOWN EuroCareCF WP3 Group on CF diagnosis
Jun 17, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Frédéric BecqOlga Zegarra-Moran
Jan 17, 2014·The Lancet. Respiratory Medicine·Michael P Boyle, Kris De Boeck
Jan 21, 2009·Nature Reviews. Drug Discovery·Alan S Verkman, Luis J V Galietta
Jun 6, 2012·Nature Structural & Molecular Biology·Christopher J Shoemaker, Rachel Green
Nov 19, 2010·The New England Journal of Medicine·Frank J AccursoBonnie W Ramsey
Sep 8, 2010·The New England Journal of Medicine·Harry C Dietz
Feb 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Douglas S AuldJames Inglese
Jun 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Stuart W PeltzDavid M Bedwell
Sep 23, 2009·The Journal of Experimental Medicine·Liutao DuRichard A Gatti
May 13, 2009·Brain : a Journal of Neurology·John VissingRonald G Haller
Apr 16, 2010·Human Molecular Genetics·Christian L LorsonMonir Shababi
May 27, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Roser TorraAlberto Ortiz
Aug 22, 2009·Current Opinion in Pulmonary Medicine·George Z Retsch-Bogart
Sep 11, 2010·Current Opinion in Pulmonary Medicine·Peter A Sloane, Steven M Rowe
Sep 21, 2013·Current Opinion in Pulmonary Medicine·Thida Ong, Bonnie W Ramsey
May 9, 2013·Current Opinion in Pediatrics·Carlos E Milla
Sep 12, 2009·Current Opinion in Neurology·Stanley F NelsonMelissa J Spencer
Sep 11, 2012·Thorax·Steven M RoweBonnie W Ramsey
Mar 7, 2009·American Journal of Respiratory and Critical Care Medicine·Felix Ratjen
Mar 21, 2009·American Journal of Respiratory and Critical Care Medicine·Bob LubambaTeresinha Leal
Jul 14, 2010·American Journal of Respiratory and Critical Care Medicine·Isabelle Sermet-GaudelusLangdon L Miller
Feb 9, 2012·American Journal of Respiratory and Critical Care Medicine·Bonnie W RamseyMichael Welsh
Jun 23, 2012·American Journal of Respiratory and Critical Care Medicine·John P Clancy, Manu Jain
Aug 4, 2012·American Journal of Respiratory and Critical Care Medicine·Paul QuintonTanja Gonska
Aug 14, 2009·American Journal of Respiratory Cell and Molecular Biology·Lawrence E OstrowskiBarbara R Grubb
Apr 18, 2013·American Journal of Respiratory Cell and Molecular Biology·Kylie M DrakeMicheala A Aldred
Aug 14, 2012·BMC Medicine·Patrick A Flume, Donald R Van Devanter
Nov 4, 2011·Orphanet Journal of Rare Diseases·Adele D'AmicoEnrico Bertini
Jun 19, 2012·Orphanet Journal of Rare Diseases·Chandree L BeaulieuAlex E Mackenzie
Sep 4, 2012·Orphanet Journal of Rare Diseases·Sara Gonzalez-HilarionFabrice Lejeune

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.